-
公开(公告)号:US20200165349A1
公开(公告)日:2020-05-28
申请号:US16779011
申请日:2020-01-31
Applicant: GENMAB A/S , BIONTECH SE
Inventor: Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号:US20200079872A1
公开(公告)日:2020-03-12
申请号:US16548883
申请日:2019-08-23
Applicant: GENMAB A/S
Inventor: Joost J. NEIJSSEN , Bart DE GOEIJ , Edward Norbert VAN DEN BRINK , Aran Frank LABRIJN , Rene HOET , Janine SCHUURMAN , Paul PARREN , Jan VAN DE WINKEL
IPC: C07K16/30 , C07K16/40 , A61K45/06 , A61K39/395 , C07K16/28 , G01N33/574 , A61P35/00
Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
公开(公告)号:US20200048304A1
公开(公告)日:2020-02-13
申请号:US16426647
申请日:2019-05-30
Applicant: GENMAB A/S
Inventor: Michael GRAMER , Amitava KUNDU , Ewald T. J. VAN DEN BREMER , Muriel VAN KAMPEN , Patrick PRIEM , Aran Frank LABRIJN , Joyce I. MEESTERS , Joost J. NEIJSSEN , Janine SCHUURMAN , Paul PARREN , Patrick VAN BERKEL , Werner L. VOS , Arnout F. GERRITSEN
Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
-
公开(公告)号:US20180215827A1
公开(公告)日:2018-08-02
申请号:US15832337
申请日:2017-12-05
Applicant: GENMAB A/S
Inventor: Bart DE GOEIJ , Simone DE HAIJ , Thilo RIEDL , Rene HOET , Ole BAADSGAARD , Jan VAN DE WINKEL , David SATIJN , Paul PARREN , Aran Frank LABRIJN , Joyce MEESTERS , Janine SCHUURMAN , Edward N. VAN DEN BRINK
CPC classification number: C07K16/2863 , A61K2039/505 , C07K16/2809 , C07K16/32 , C07K2317/31 , C07K2317/52 , C07K2317/526 , C07K2317/528 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
公开(公告)号:US20180044431A1
公开(公告)日:2018-02-15
申请号:US15626866
申请日:2017-06-19
Applicant: GENMAB A/S
Inventor: Sandra VERPLOEGEN , David P.E. SATIJN , Rene M.A. HOET , Paul PARREN , Jan VAN DE WINKEL , Vibeke Miller BREINHOLT , Eva EHRNROOTH , Ole BAADSGAARD , Tom VINK , Willam Karel BLEEKER , Mischa HOUTKAMP , Maroeska OUDSHOORN , Rob N. DE JONG
IPC: C07K16/36 , A61K39/395 , A61K39/00
CPC classification number: C07K16/36 , A61K39/395 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
-
公开(公告)号:US20170029521A1
公开(公告)日:2017-02-02
申请号:US15197496
申请日:2016-06-29
Applicant: GENMAB A/S
Inventor: Jan VAN DE WINKEL , Tom VINK , Janine SCHUURMAN , Paul PARREN , Rob AALBERSE , Marijn VAN DER NEUT KOLFSCHOTEN
Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
Abstract translation: 本发明涉及稳定的IgG4抗体,涉及产生此类抗体的方法以及此类抗体作为药物的用途。 在一个主要方面,本发明涉及一种稳定的IgG4抗体,其包含重链和轻链,其中所述重链包含具有在位置(409)处的Arg残基取代的人IgG4恒定区, 位置(405)或位置(370)处的Lys残基。
-
公开(公告)号:US20160333095A1
公开(公告)日:2016-11-17
申请号:US15110414
申请日:2015-01-08
Applicant: GENMAB A/S
Inventor: Edward Norbert VAN DEN BRINK , Joost J. NEIJSSEN , Aran Frank LABRIJN , Joyce MEESTERS , Janine SCHUURMAN , Isil ALTINTAS , Paul PARREN , Rik RADEMAKER
CPC classification number: C07K16/2809 , A61K2039/505 , C07K16/1063 , C07K16/2863 , C07K16/2887 , C07K16/2896 , C07K16/32 , C07K16/4241 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/732 , C07K2317/734 , C07K2317/74 , C07K2317/75 , C07K2317/90 , C07K2317/92 , G01N33/6872 , G01N2333/7051
Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
Abstract translation: 本发明涉及结合CD3的人源化或嵌合抗体。 此外,它还涉及双特异性抗体,组合物,药物组合物,所述抗体在治疗疾病中的用途,以及治疗方法。
-
公开(公告)号:US20160168247A1
公开(公告)日:2016-06-16
申请号:US14902757
申请日:2014-07-04
Applicant: GENMAB A/S
Inventor: Edward VAN DEN BRINK , Joost J. NEIJSSEN , Aran Frank LABRIJN , Joyce MEESTERS , Janine SCHUURMAN , Paul PARREN
Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
-
公开(公告)号:US20250066506A1
公开(公告)日:2025-02-27
申请号:US18596319
申请日:2024-03-05
Applicant: GENMAB A/S
Inventor: Bart DE GOEIJ , Patrick VAN BERKEL , Kristin STRUMANE , Aran Frank LABRIJN , Joost J. NEIJSSEN , Joyce I. MEESTERS , Paul PARREN , Janine SCHUURMAN
Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
-
公开(公告)号:US20240294661A1
公开(公告)日:2024-09-05
申请号:US18526959
申请日:2023-12-01
Applicant: Genmab A/S
Inventor: David SATIJN , Sandra VERPLOEGEN , Wim BLEEKER , Steen LISBY , Jan VAN DE WINKEL , Patrick VAN BERKEL , Paul PARREN
CPC classification number: C07K16/30 , A61K45/06 , A61K47/6817 , A61K47/6849 , C07K16/36 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
-
-
-
-
-
-
-
-
-